AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18311770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year coaching program for healthy physical activity
Number of subjects: 228
Study 18311770 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without additional coaching)
Number of subjects: 228
Study 16284232 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg daily
Number of subjects: 19
Study 16284232 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily
Number of subjects: 19
Study 16284232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12744544 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing supplemental oxygen
Number of subjects: 20
Study 12744544 — intervention group
Group type: COMPARATOR
Intervention: Breathing air
Number of subjects: 20
Study 10902987 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy supplement (1171 kJ + 12 mg iron)
Number of subjects: 136
Study 10902987 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement (209 kJ + 12 mg iron)
Number of subjects: 136
Study 10902987 — intervention group
Group type: COMPARATOR
Intervention: Control (104 kJ)
Number of subjects: 136
Study 9166392 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 464
Study 9166392 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + Vit D (2 mg estradiol valerate and 1 mg cyproterone acetate + 300 IU/day vitamin D3)
Number of subjects: 464
Study 9166392 — intervention group
Group type: COMPARATOR
Intervention: Vit D (300 IU/day)
Number of subjects: 464
Study 9166392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium lactate; 93 mg Ca2+/day)
Number of subjects: 464
Study 9166392 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 464
Study 9166392 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + Vit D
Number of subjects: 464
Study 9166392 — intervention group
Group type: COMPARATOR
Intervention: Vit D
Number of subjects: 464
Study 9166392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 8335785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants applied with a bonding agent on wet enamel
Number of subjects: 0
Study 8335785 — intervention group
Group type: COMPARATOR
Intervention: Sealants applied without a bonding agent on wet enamel
Number of subjects: 0
Study 3541421 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN) given orally within the current therapeutic range
Number of subjects: 0
Study 3541421 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN)
Number of subjects: 0
Study 30246754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite (FRC) space maintainer (INFIBRA®: Reinforcing ribbon, Bioloren, Italy)
Number of subjects: 50
Study 30246754 — intervention group
Group type: COMPARATOR
Intervention: Band and loop space maintainers
Number of subjects: 50
Study 26573925 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days)
Number of subjects: 90
Study 26573925 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 90
Study 26573925 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 23676311 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 138)
Number of subjects: 320
Study 23676311 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 152)
Number of subjects: 320
Study 22628062 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram formulation by Grupo Tecnimede
Number of subjects: 24
Study 22628062 — intervention group
Group type: COMPARATOR
Intervention: European reference formulation
Number of subjects: 24
Study 22628062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 20458613 — intervention group
Group type: EXPERIMENTAL
Intervention: New reusable skin-protective cuff
Number of subjects: 0
Study 20458613 — intervention group
Group type: COMPARATOR
Intervention: Control (standard sphygmomanometer cuff)
Number of subjects: 0
Study 18262771 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99
Study 18262771 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 99
Study 18262771 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 99
Study 18262771 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 99
Study 18262771 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP IIIA criteria
Number of subjects: 99
Study 18262771 — intervention group
Group type: EXPERIMENTAL
Intervention: IDF criteria
Number of subjects: 99
Study 16171242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg t.i.d.
Number of subjects: 24
Study 16171242 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg t.i.d.
Number of subjects: 24
Study 16171242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14673757 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis
Number of subjects: 643
Study 14673757 — intervention group
Group type: COMPARATOR
Intervention: No azithromycin prophylaxis
Number of subjects: 643
Study 10227337 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg twice daily)
Number of subjects: 437
Study 10227337 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 220 microg twice daily
Number of subjects: 437
Study 8737434 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group face‐to‐face intervention
Number of subjects: 45
Study 8737434 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal seminar
Number of subjects: 45
Study 8737434 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 1650315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac, 300 mg/day
Number of subjects: 9
Study 1650315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6259766 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of cephalothin intravenously
Number of subjects: 171
Study 6259766 — intervention group
Group type: COMPARATOR
Intervention: No parenteral antibiotics
Number of subjects: 171
Study 30616441 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Balanced program (progressive balance training, group sessions twice a week for 10 weeks)
Number of subjects: 15
Study 30048979 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 30048979 — intervention group
Group type: COMPARATOR
Intervention: Control (no metformin)
Number of subjects: 20
Study 28359259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative group (Propofol and sufentanil)
Number of subjects: 1033
Study 28359259 — intervention group
Group type: COMPARATOR
Intervention: Routine group (without sedative)
Number of subjects: 1033
Study 28359259 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 1033
Study 26805909 — intervention group
Group type: EXPERIMENTAL
Intervention: RT combined with task-specific training (RTT)
Number of subjects: 21
Study 26805909 — intervention group
Group type: COMPARATOR
Intervention: RT combined with impairment-oriented training (RTI)
Number of subjects: 21
Study 25423631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 29
Study 25423631 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab
Number of subjects: 29
Study 21670709 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyaxial locking screw plate (Group 1)
Number of subjects: 56
Study 21670709 — intervention group
Group type: COMPARATOR
Intervention: Nonpolyaxial locking screw plate (Group 2)
Number of subjects: 56
Study 18379759 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 18
Study 18379759 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oxycodone
Number of subjects: 18
Study 18379759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16521188 — intervention group
Group type: EXPERIMENTAL
Intervention: Topaal
Number of subjects: 121
Study 16521188 — intervention group
Group type: COMPARATOR
Intervention: Nacid
Number of subjects: 121
Study 12969112 — intervention group
Group type: EXPERIMENTAL
Intervention: WarmTouch blower with CareDrape blanket
Number of subjects: 6
Study 12969112 — intervention group
Group type: COMPARATOR
Intervention: BairHugger system
Number of subjects: 6
Study 12969112 — intervention group
Group type: EXPERIMENTAL
Intervention: ThermaCare system
Number of subjects: 6
Study 12969112 — intervention group
Group type: EXPERIMENTAL
Intervention: WarmAir system
Number of subjects: 6
Study 10634646 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 0
Study 10634646 — intervention group
Group type: EXPERIMENTAL
Intervention: HDMP
Number of subjects: 0
Study 10634646 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF + HDMP
Number of subjects: 0
Study 10634646 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 8729209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (450 or 600 mg/d)
Number of subjects: 200
Study 1420648 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion (10 mg plus 7 mg/hr for a total of 94 mg)
Number of subjects: 8
Study 3841228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 40 mg
Number of subjects: 12
Study 3841228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 10 mg
Number of subjects: 12
Study 31158474 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (EXER) for 16 weeks
Number of subjects: 96
Study 31158474 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group receiving lifestyle counselling (CONT) for 16 weeks
Number of subjects: 96
Study 30920880 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus fluorouracil
Number of subjects: 436
Study 30920880 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus fluorouracil
Number of subjects: 436
Study 28250198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (3 education visits and specialist review of care plans)
Number of subjects: 268
Study 28250198 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 268
Study 26009915 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnion membrane (AM) + deproteinized bovine bone mineral (BBM)
Number of subjects: 10
Study 26009915 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane (CM) + deproteinized bovine bone mineral (BBM)
Number of subjects: 10
Study 22952209 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 280
Study 22952209 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-CM)
Number of subjects: 280
Study 21358504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/d N-3 (omega-3 fatty acids)
Number of subjects: 45
Study 21358504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21358504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 19258546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (800 IU/d)
Number of subjects: 92
Study 19258546 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2.0 g/d)
Number of subjects: 92
Study 19258546 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D3
Number of subjects: 92
Study 19258546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 19258546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 92
Study 19258546 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 92
Study 17008194 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg daily for 3 days prior to quit date, then 50 mg/day for 8 weeks)
Number of subjects: 110
Study 17008194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 17008194 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 110
Study 14676759 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg penicillin G potassium troches (Cankercillin)
Number of subjects: 100
Study 14676759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14676759 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 100
Study 10708160 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 mg bolus injection)
Number of subjects: 12
Study 9089853 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block with 0.6 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine before incision (n = 28)
Number of subjects: 51
Study 9089853 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural block with 0.6 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine after surgery (n = 23)
Number of subjects: 51
Study 1491501 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 15
Study 1491501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2871079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobecutan-gauze dressing
Number of subjects: 145
Study 2871079 — intervention group
Group type: COMPARATOR
Intervention: Op-site dressing
Number of subjects: 145
Study 31302685 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C decrease (observed in NHANES III)
Number of subjects: 4756
Study 31302685 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C decrease (observed in HKOS)
Number of subjects: 4756
Study 31302685 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted LDL-C decrease (Mendelian randomization analysis)
Number of subjects: 4756
Study 31302685 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins' LDL-C-lowering proxies
Number of subjects: 4756
Study 31302685 — intervention group
Group type: COMPARATOR
Intervention: Increase in LDL-C
Number of subjects: 4756
Study 29352812 — intervention group
Group type: COMPARATOR
Intervention: Standardized verbal instructions
Number of subjects: 85
Study 29352812 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized verbal instructions in conjunction with visual aids
Number of subjects: 85
Study 27699485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 19
Study 27699485 — intervention group
Group type: COMPARATOR
Intervention: Control (seated rest)
Number of subjects: 19
Study 24021667 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic Endoscopic Evaluation of Swallowing
Number of subjects: 138
Study 24021667 — intervention group
Group type: COMPARATOR
Intervention: Facial‐Oral Tract Therapy
Number of subjects: 138
Study 22260946 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device (LVAD) support
Number of subjects: 401
Study 20080201 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 801
Study 20080201 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 801
Study 20080201 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 microg twice-daily
Number of subjects: 801
Study 20080201 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 microg od
Number of subjects: 801
Study 20080201 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 75 microg
Number of subjects: 801
Study 20080201 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 600 microg
Number of subjects: 801
Study 18724190 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Reduction Intervention
Number of subjects: 32
Study 18724190 — intervention group
Group type: COMPARATOR
Intervention: Comparison interventions
Number of subjects: 32
Study 16793625 — intervention group
Group type: EXPERIMENTAL
Intervention: Delisheng injection combined with IMRT
Number of subjects: 66
Study 16793625 — intervention group
Group type: COMPARATOR
Intervention: IMRT alone
Number of subjects: 66
Study 15115135 — intervention group
Group type: EXPERIMENTAL
Intervention: Okavax only
Number of subjects: 299
Study 15115135 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-II only
Number of subjects: 299
Study 15115135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines concomitantly
Number of subjects: 299
Study 15115135 — intervention group
Group type: COMPARATOR
Intervention: MMR-II with Okavax
Number of subjects: 299
Study 10740401 — intervention group
Group type: EXPERIMENTAL
Intervention: Long chain triglycerides (20% Intralipid)
Number of subjects: 12
Study 10740401 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium- and long-chain triglycerides (1:1 mixture, 20% Lipofundina)
Number of subjects: 12
Study 8737324 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 20
Study 8737324 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 20
Study 1595104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 75 mg dipyridamole and 330 mg acetylsalicylic acid three times a day
Number of subjects: 216
Study 1595104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 6142906 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg) with ethanol (60 ml vodka + 60 ml water)
Number of subjects: 5
Study 6142906 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (0.5 mg) with water (100 to 200 ml)
Number of subjects: 5
Study 31579014 — intervention group
Group type: EXPERIMENTAL
Intervention: MOOD (self-guided internet-based intervention)
Number of subjects: 125
Study 31579014 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 125
Study 28670938 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily for four weeks
Number of subjects: 60
Study 28670938 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 60
Study 27038034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucocorticosteroid treatment
Number of subjects: 0
Study 27038034 — intervention group
Group type: COMPARATOR
Intervention: Standard dose glucocorticosteroid treatment
Number of subjects: 0
Study 27038034 — intervention group
Group type: EXPERIMENTAL
Intervention: Another type of high-dose glucocorticosteroid treatment
Number of subjects: 0
Study 25381721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ETV once daily; 2 g RGT three times daily
Number of subjects: 1000
Study 25381721 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ETV once daily; 2 g RGT dummy agent three times daily
Number of subjects: 1000
Study 23377592 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care program implemented by Community Health Practitioners (CHPs) for 6 weeks, 2 hours per week
Number of subjects: 290
Study 23377592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 290
Study 20795444 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100
Study 20795444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 100
Study 20795444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide and dexamethasone
Number of subjects: 100
Study 20795444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 17511246 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-threat group
Number of subjects: 0
Study 17511246 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat group
Number of subjects: 0
Study 17511246 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16040370 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drug alcohol intervention
Number of subjects: 448
Study 11989836 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat grass juice (100 cc daily for 1 month)
Number of subjects: 23
Study 11989836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching to wheat grass juice)
Number of subjects: 23
Study 10084293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine (5 mg/kg for 15 patients and 25 mg/kg for 5 patients) with intravenous iron saccharate (20 mg/HD session) for four months.
Number of subjects: 20
Study 10084293 — intervention group
Group type: COMPARATOR
Intervention: Placebo with intravenous iron saccharate (20 mg/HD session) for four months.
Number of subjects: 20
Study 10084293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine with iron supplementation.
Number of subjects: 20
Study 10084293 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of iron supplementation in both groups.
Number of subjects: 20
Study 8846249 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol drops
Number of subjects: 37
Study 8846249 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 37
Study 2127377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin spray (0.4 mg)
Number of subjects: 49
Study 2127377 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin tablet (0.4 mg)
Number of subjects: 49
Study 7282589 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet
Number of subjects: 9
Study 7282589 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet with 5% carbohydrate
Number of subjects: 9
Study 7282589 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet after isocaloric diet
Number of subjects: 9
Study 30827769 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration (HC) 5% sodium hypochlorite
Number of subjects: 100
Study 30827769 — intervention group
Group type: COMPARATOR
Intervention: Low-concentration (LC) 1% sodium hypochlorite
Number of subjects: 100
Study 28732483 — intervention group
Group type: COMPARATOR
Intervention: Self-paced walking (without dual-task)
Number of subjects: 32
Study 28732483 — intervention group
Group type: COMPARATOR
Intervention: Self-paced walking with dual-task
Number of subjects: 32
Study 28732483 — intervention group
Group type: COMPARATOR
Intervention: Fast walking
Number of subjects: 32
Study 28732483 — intervention group
Group type: COMPARATOR
Intervention: Fast walking with dual-task
Number of subjects: 32
Study 28732483 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced walking
Number of subjects: 32